# A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers

> **NCT01243502** · PHASE1 · COMPLETED · sponsor: **Creabilis SA** · enrollment: 16 (actual)

## Conditions studied

- Safety

## Interventions

- **DRUG:** 0.01% CT327 (or placebo)
- **DRUG:** 0.001% CT327 (or placebo)

## Key facts

- **NCT ID:** NCT01243502
- **Lead sponsor:** Creabilis SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2010-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243502, "A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01243502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*